Literature DB >> 34243600

Phytochemicals reverse P-glycoprotein mediated multidrug resistance via signal transduction pathways.

M Ganesan1, G Kanimozhi2, B Pradhapsingh1, Haseeb A Khan3, Abdullah S Alhomida3, Aishah Ekhzaimy4, G R Brindha5, N Rajendra Prasad6.   

Abstract

P-glycoprotein, encoded by ATP-binding cassette transporters B1 gene (ABCB1), renders multidrug resistance (MDR) during cancer chemotherapy. Several synthetic small molecule inhibitors affect P-glycoprotein (P-gp) transport function in MDR tumor cells. However, inhibition of P-gp transport function adversely accumulates chemotherapeutic drugs in non-target normal tissues. Moreover, most small-molecule P-gp inhibitors failed in the clinical trials due to the low therapeutic window at the maximum tolerated dose. Therefore, downregulation of ABCB1-gene expression (P-gp) in tumor tissues seems to be a novel approach rather than inhibiting its transport function for the reversal of multidrug resistance (MDR). Several plant-derived phytochemicals modulate various signal transduction pathways and inhibit translocation of transcription factors, thereby reverses P-gp mediated MDR in tumor cells. Therefore, phytochemicals may be considered an alternative to synthetic small molecule P-gp inhibitors for the reversal of MDR in cancer cells. This review discussed the role of natural phytochemicals that modulate ABCB1 expression through various signal transduction pathways in MDR cancer cells. Therefore, modulating the cell signaling pathways by phytochemicals might play crucial roles in modulating ABCB1 gene expression and the reversal of MDR.
Copyright © 2021 The Authors. Published by Elsevier Masson SAS.. All rights reserved.

Entities:  

Keywords:  Cellular signaling; Multidrug resistance; Natural products; P-glycoprotein; Phytochemicals

Mesh:

Substances:

Year:  2021        PMID: 34243600     DOI: 10.1016/j.biopha.2021.111632

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  6 in total

1.  Clinical significance and correlation of miR-200c and P-gp expression in gastric cancer and the effects on multidrug resistance.

Authors:  Shen Wang; Jien Guo; Zhenzhou Mo; Xiangcheng Shi; Chongxiao Qu
Journal:  J Gastrointest Oncol       Date:  2022-04

Review 2.  Multidrug Resistance in Cancer Cells: Focus on a Possible Strategy Plan to Address Colon Carcinoma Cells.

Authors:  Chenmala Karthika; Raman Sureshkumar; Mehrukh Zehravi; Rokeya Akter; Faraat Ali; Sarker Ramproshad; Banani Mondal; Milton Kumar Kundu; Abhijit Dey; Md Habibur Rahman; Angela Antonescu; Simona Cavalu
Journal:  Life (Basel)       Date:  2022-05-30

3.  DHW-221, a Dual PI3K/mTOR Inhibitor, Overcomes Multidrug Resistance by Targeting P-Glycoprotein (P-gp/ABCB1) and Akt-Mediated FOXO3a Nuclear Translocation in Non-small Cell Lung Cancer.

Authors:  Mingyue Liu; Chang Xu; Xiaochun Qin; Wenwu Liu; Deping Li; Hui Jia; Xudong Gao; Yuting Wu; Qiong Wu; Xiangbo Xu; Bo Xing; Xiaowen Jiang; Hongyuan Lu; Yingshi Zhang; Huaiwei Ding; Qingchun Zhao
Journal:  Front Oncol       Date:  2022-05-13       Impact factor: 5.738

4.  Ketone-selenoesters as potential anticancer and multidrug resistance modulation agents in 2D and 3D ovarian and breast cancer in vitro models.

Authors:  Simona Dobiasová; Nikoletta Szemerédi; Denisa Kučerová; Kamila Koucká; Radka Václavíková; Helena Gbelcová; Tomáš Ruml; Enrique Domínguez-Álvarez; Gabriella Spengler; Jitka Viktorová
Journal:  Sci Rep       Date:  2022-04-21       Impact factor: 4.996

Review 5.  Emerging nanotechnology-based therapeutics to combat multidrug-resistant cancer.

Authors:  Priya Yadav; Suresh V Ambudkar; N Rajendra Prasad
Journal:  J Nanobiotechnology       Date:  2022-09-24       Impact factor: 9.429

6.  Phytol and Heptacosane Are Possible Tools to Overcome Multidrug Resistance in an In Vitro Model of Acute Myeloid Leukemia.

Authors:  Manuela Labbozzetta; Paola Poma; Marco Tutone; James A McCubrey; Maurizio Sajeva; Monica Notarbartolo
Journal:  Pharmaceuticals (Basel)       Date:  2022-03-15
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.